Le Lézard
Classified in: Health, Business
Subjects: CXP, MAT

Construction Advancing at Alternabis Farms



VICTORIA, Aug. 10, 2018 /CNW/ - Alternabis Farms Ltd. ("Alternabis" or the "Company") is pleased to announce construction is advancing at their new state-of-the-art cannabis production facility on Vancouver Island, British Columbia.

Alternabis (CNW Group/Alternabis)

The family-owned and operated company applied to become a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR) in 2014. The facility is located on a 100-acre farm that is agriculturally zoned and approved for cannabis cultivation.

"Alternabis is a passionate family business with the goal of producing premium and innovative cannabis at an affordable price," said Max Walker, Director of Marketing & Sales.

The 16,000 sq. ft. high-tech and sustainable two-floor facility will house a vast underground area and an upper-level greenhouse. This facility will position Alternabis as a new player in the Canadian cannabis market and allow the company to collect, research and breed cultivars from around the world.

"By building a two floor facility we maximize production space while minimizing our ecological footprint. We plan to use renewable energy as much as possible to run our facility. We have made our commitment to the environment an integral part of our strategy," said Bryan Walker, Director of Cultivation.

The company plans to differentiate itself from competitors by focusing on a patient base that desires exceptional cultivars and growing methods. This requires continuous R&D in order to provide medical patients with the best cannabis available.

"Patients are turning towards specialized cannabis to fulfill their needs," said Patrick Walker, Director of Operations. "Alternabis will produce this high-quality cannabis and make it affordable, accessible and sustainable."

With the new regulations allowing outdoor cannabis production, Alternabis has started to develop the 100-acre farm to produce outdoor cannabis that will be processed in a large extraction facility located on the property.

The property is located in the Cowichan region which is Canada's only Maritime Mediterranean climatic zone resulting in the warmest mean year-round temperature anywhere in Canada.

The indoor facility is expected to be operational by the end of 2018 and the company anticipates a license to cultivate at the beginning of 2019.

About Alternabis

Alternabis is a family-owned and operated business committed to helping medical patients with innovative cannabis products. Their focus on unique cultivars and cannabinoids will sprout some of the highest quality cannabis in the emerging Canadian market.

SOURCE Alternabis


These press releases may also interest you

10 déc 2018
Bryce Williams, president & CEO of HealthMine, Inc., the Health Action as a Service company (HAaaS), will be presenting at the 9th Annual RISE Star Ratings Master Class.  Williams will present on "Improving star quality ratings: how to think like a...

10 déc 2018
The food recall warning issued on November 9, 2018 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Canada Herb is...

10 déc 2018
HCP, Inc. (the "Company") announced today that it has agreed to sell 15,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 13,000,000 shares offered on a forward basis in connection with the...

10 déc 2018
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have...

10 déc 2018
Pascal Biosciences Inc. ("Pascal" or the "Company"), a drug discovery and development company, announced today it will host a year-end investor update webcast on Thursday, Dec. 17, 2018 at 1:30 p.m. PST. Dr. Patrick Gray, CEO of Pascal Biosciences,...

10 déc 2018
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"), a clinical stage oncology...




News published on 10 august 2018 at 18:06 and distributed by: